top of page

ABOUT US

CAPITAL PARTNER

Validating the vision and propelling growth

As a Blackstone Life Sciences portfolio company, Uniquity Bio has access to ongoing capital resources to fund our clinical drug development, operations, and core capabilities. We operate independently under the Blackstone umbrella and enjoy a partnership that extends beyond capital investment to include scientific support and a shared commitment to excellence.

Nexstone-Immunology-Capital-Partner.jpg
With Blackstone’s investment, our unique and sustainable business model maximizes the value creation of individual drug assets while fueling pipeline growth, operational agility, and clinical execution.

As a nimble startup with experienced leaders and capital resources, Uniquity Bio is well-positioned to develop promising therapeutics and partner with leading pharmaceutical companies to bring important new medicines to patients.

bottom of page